EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tumor-expressed HNF1A promotes antitumor immunity by activating tumor-infiltrating CD8+ T cells

Tadayuki Nakashima, Yasuto Yoneshima, Toshifumi Ninomiya, Shun Mizusaki, Ritsu Ibusuki, Yuki Ikematsu, Daisuke Shibahara, Kohei Otsubo, Eiji Iwama, Kentaro Tanaka, Isamu Okamoto

Cancer Immunology, Immunotherapy · 22.08.2026 · 75 (12)

DOI: 10.1007/s00262-026-04533-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 22.08.2026. Verfasst von Tadayuki Nakashima und 10 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of immune checkpoint inhibitors has improved the treatment outcomes for patients with many types of cancer. However, the clinical benefits remain limited in many patients, highlighting the need for novel therapeutic strategies to enhance antitumor immunity. Hepatocyte nuclear factor 1A (HNF1A) is a transcription factor that regulates the expression of several liver-specific genes, and its expression is increased in certain cancers, such as colon and non-small cell lung cancer (NSCLC), compared with normal tissue. However, the effects of HNF1A on antitumor immunity remain unknown. Here, we show that colon cancer and NSCLC expressing HNF1A activate antitumor immunity. HNF1A-overexpressing cancer cells activated T-cell-mediated anticancer cytotoxicity when co-cultured with peripheral blood mononuclear cell-derived T cells. In a syngeneic mouse model, MC38 colon adenocarcinoma growth was suppressed after subcutaneous injection of HNF1A-overexpressing cancer cells. Flow cytometry analysis of tumor-infiltrating T cells showed that CD8 + T cells increased and were functionally activated in tumors overexpressing HNF1A. Treatment with an anti-PD-1 monoclonal antibody reduced tumor growth in HNF1A-overexpressing tumors. These results suggest that HNF1A plays a role in antitumor immunity and may influence the response to immune checkpoint blockade.

Zitieren

APA

Nakashima, T., Yoneshima, Y., Ninomiya, T., Mizusaki, S., Ibusuki, R., Ikematsu, Y., Shibahara, D., Otsubo, K., Iwama, E., Tanaka, K., & Okamoto, I. (2026). Tumor-expressed HNF1A promotes antitumor immunity by activating tumor-infiltrating CD8+ T cells. Cancer Immunology, Immunotherapy, 75(12). https://doi.org/10.1007/s00262-026-04533-6

Vancouver

Nakashima T, Yoneshima Y, Ninomiya T, Mizusaki S, Ibusuki R, Ikematsu Y, et al. Tumor-expressed HNF1A promotes antitumor immunity by activating tumor-infiltrating CD8+ T cells. Cancer Immunology, Immunotherapy. 2026;75(12). doi:10.1007/s00262-026-04533-6

BibTeX
@article{Nakashima2026,
  author = {Nakashima, Tadayuki and Yoneshima, Yasuto and Ninomiya, Toshifumi and Mizusaki, Shun and Ibusuki, Ritsu and Ikematsu, Yuki and Shibahara, Daisuke and Otsubo, Kohei and Iwama, Eiji and Tanaka, Kentaro and Okamoto, Isamu},
  title = {Tumor-expressed HNF1A promotes antitumor immunity by activating tumor-infiltrating CD8+ T cells},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {12},
  doi = {10.1007/s00262-026-04533-6}
}
Kostenlos starten →